Drug Profile
Anatabine
Alternative Names: Anatabine citrate; Controlled release; RCP-006Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Star Scientific
- Developer Rock Creek Pharmaceuticals Inc; Roskamp Institute; Zenith Technology Corporation
- Class Alkaloids; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Cholinergic receptor agonists; Glycogen synthase kinase 3 beta inhibitors; NF-kappa B inhibitors; STAT3 transcription factor inhibitors; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Inflammation; Multiple sclerosis; Neurological disorders; Ulcerative colitis
- Discontinued Brain injuries; Cognition disorders; Osteoarthritis; Psoriasis; Smoking withdrawal; Thyroiditis
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Brain injuries in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Cognition disorders in USA (unspecified route)
- 22 Feb 2023 Discontinued - Preclinical for Osteoarthritis in USA (PO)